| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Puma Biotechnology Inc$8
+0.1 (+1.27%)
C 58Pipeline Score Undervalued Pharma · Clinical
Market Cap
360.37 M
EPS
0.49
P/E Ratio
14.83 $
Value Trade
1.56 M
SEC Financials
Q1 2026Dilution Risk
Revenue
44.81 M
R&D Expenses
19.80 M
Operating CF
15.42 M
Total Assets
192.70 M
Total Liabilities
64.28 M
Equity
128.42 M
D/E Ratio
12,345
-0.28 %
Week
-3.01 %
1 Month
4.42 %
3 Month
45.98 %
6 Month
-33.52 %
5 Year
-29.2 %
All Time
Cash Data
Cash Position
101.55 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
342.26 K
52 Week Range
3.03 - 7.90
% held by Insiders
23.71 %
% held by Institutions
66.76 %
Enterprise Value
272.69 M
Total Shares
50.40 M
Short %
9.53 %
Float Shares
38.06 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Puma Biotechnology Inc
240Total events
2Upcoming
88Tier-1 (high impact)
2012 – 2026Coverage
Upcoming catalysts 2
Event history 238
May 4, 2026
▲Debt Royalty FinancingCorporate
Final payment under 2021 Note Purchase Agreement remitted, debt reduced to zero
Q2 2026
◆Oral PresentationAlisertibPresentation
Interim data from ALISCA-Breast1 (alisertib + endocrine therapy) to be presented
HER2-negative, hormone receptor-positive metastatic breast cancersource ↗
Mar 2, 2026
◆Oral PresentationPresentation
Puma Biotechnology presentation at TD Cowen 46th Annual Health Care Conference
2022
◆FDA Feedback ReceivedNeratinibApprovedFDA Meeting
Meeting with FDA to discuss accelerated approval pathway for neratinib in NSCLC with EGFR exon 18 mutations
non-small cell lung cancer with EGFR exon 18 mutationssource ↗
Q4 2021
◆Topline ReadoutNeratinibApprovedClinical Data
Topline data from randomized cohort of SUMMIT trial in HR+ HER2-mutated breast cancer
hormone receptor positive breast cancer with HER2 mutationsource ↗
Q4 2021
◆Pre NDA MeetingNeratinibApprovedFDA Meeting
Pre-NDA meeting with FDA for accelerated approval of neratinib in HER2-mutated HR+ breast cancer
HER2-mutated hormone receptor positive breast cancersource ↗
Q2 2021
◆Enrollment CompleteNeratinibApprovedTrial
Complete enrollment in randomized cohort of Phase II SUMMIT trial of neratinib in HR+ HER2-mutated breast cancer
hormone receptor positive breast cancer that has a HER2 mutationsource ↗
Drug Pipeline Intelligence
C58
Pipeline Score $1.4B
Pipeline ValueUndervalued
Valuation Signal5
Drugs Scored3.8x
rNPV / MCap Top 85%
Micro Cap (rank 138 of 911)
Percentile RankPuma Biotechnology Inc carries a moderate pipeline score (58/100), with $3.4B risk-adjusted pipeline value, led by neratinib in HER2+ Metastatic Breast Cancer (MBC) (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neratinib Small molecule | Breast Cancer | Phase 3 | NCT03377387 | 46% | $2.6B | ACTIVE NOT_RECRUITING | 3,929 | - | - | Dec 1, 2026 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PB272 | breast cancer | Phase 3 | 2015-06-01 | primary: hazard ratio 0.67, p value 0.009, two year dfs rate neratinib 93.9%, two year dfs rate placebo 91.6%; secondary: hazard ratio 0.63, p value 0.002, two year dfs dcis rate neratinib 93.9%, two year dfs dcis rate placebo 91.0% Read More | Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival Read More | |
PB272 | breast cancer | Phase 3 | 2015-06-01 | primary: hazard ratio 0.67, p value 0.009, two year dfs rate neratinib 93.9%, two year dfs rate placebo 91.6%; secondary: hazard ratio 0.63, p value 0.002, two year dfs dcis rate neratinib 93.9%, two year dfs dcis rate placebo 91.0% Read More | Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival Read More | |
PB272 | breast cancer | Phase 3 | 2015-06-01 | primary: hazard ratio 0.67, p value 0.009, two year dfs rate neratinib 93.9%, two year dfs rate placebo 91.6%; secondary: hazard ratio 0.63, p value 0.002, two year dfs dcis rate neratinib 93.9%, two year dfs dcis rate placebo 91.0% Read More | Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PBYI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PBYI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PBYIPuma Biotechnology Reports First Quarter 2026 Financial Results
Puma Biotechnology reported its financial results for Q1 2026, showing a net loss of $3.8 million, down from a net income of $3.0 million in Q1 2025. Despite a slight decrease in product revenue from NERLYNX, the company raised its revenue guidance for 2026, citing increased demand. Additionally, Puma is focusing on expanding clinical trials for alisertib, with promising interim data supporting its development.
Read more →PBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - April 2, 2026
Puma Biotechnology announced the approval of inducement restricted stock unit awards for five new non-executive employees on April 1, 2026. The awards, totaling 31,625 shares, will vest over three years as part of the company's strategy to attract new talent. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and supports Puma's ongoing commitment to cancer care innovation.
Read more →PBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology has reported inducement awards in compliance with Nasdaq Listing Rule 5635(c)(4). The details of the awards and their implications for the company were not disclosed in the article. This announcement is part of Puma's ongoing corporate governance and compliance efforts.
Read more →PBYI▼ -25%on this news
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
Puma Biotechnology reported its financial results for Q4 and full year 2025, showing a net income of $13.4 million for Q4, down from $19.3 million in Q4 2024. Despite this decline, the company has maintained profitability for three consecutive years. Product revenue from NERLYNX increased, contributing to a total revenue of $75.5 million in Q4 2025. The company anticipates continued profitability into 2026 and has outlined key clinical milestones for its alisertib trials.
Read more →PBYI▲ +5.3%on this news· ran to -20% by day 3shared move
Puma Biotechnology to Present at TD Cowen’s 46th Annual Health Care Conference
Puma Biotechnology will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CEO Alan H. Auerbach will provide an overview of the company during the event. The conference will take place at the Boston Marriott Copley Place, and a live webcast will be available on Puma's website.
Read more →PBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - February 4, 2026
Puma Biotechnology announced the approval of inducement restricted stock unit awards for two new non-executive employees. The awards, covering 14,750 shares, will vest over three years and are part of Puma's 2017 Employment Inducement Incentive Award Plan. This move aims to attract talent while adhering to Nasdaq Listing Rule 5635(c)(4).
Read more →PBYIPuma Biotechnology Reports Second Quarter 2021 Financial Results
Puma Biotechnology Reports Second Quarter 2021 Financial Results LOS ANGELES, Calif., Aug. 5, 2021 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2021. Unless otherwise stated, all comparis
Read more →PBYIPuma Biotechnology Reports First Quarter 2021 Financial Results
Puma Biotechnology Reports First Quarter 2021 Financial Results LOS ANGELES, Calif., May 6, 2021 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2021. Unless otherwise stated, all comparison
Read more →PBYIPuma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Biotechnology Reports Fourth Quarter and Full Year Financial Results LOS ANGELES, Calif., Feb. 25, 2021 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2020. Unless otherwise st
Read more →PBYIPuma Biotechnology Reports Third Quarter 2020 Financial Results
Puma Biotechnology Reports Third Quarter 2020 Financial Results LOS ANGELES, Calif., Nov. 5, 2020 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2020. Unless otherwise stated, all compa
Read more →PBYIPuma Biotechnology Reports Second Quarter 2020 Financial Results
Puma Biotechnology Reports Second Quarter 2020 Financial Results LOS ANGELES, Calif., Aug. 6, 2020 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2020. Unless otherwise stated, all comparis
Read more →PBYIPuma Biotechnology Reports First Quarter 2020 Financial Results
Puma Biotechnology Reports First Quarter 2020 Financial Results LOS ANGELES, Calif., May 7, 2020 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2020. Unless otherwise stated, all comparison
Read more →PBYIPuma Biotechnology J.P. Morgan 2020 Healthcare Conference January 2020 Copyright 2020 Puma Biotechnology Forward-Looking Safe Harbor Statement This presentation contains forward-looking statements, including statements r
Puma Biotechnology J.P. Morgan 2020 Healthcare Conference January 2020 Copyright 2020 Puma Biotechnology Forward-Looking Safe Harbor Statement This presentation contains forward-looking statements, including statements regarding the benefits of NERLYNX (neratinib) and neratinib
Read more →PBYIPuma Biotechnology Reports Third Quarter 2019 Financial Results
Puma Biotechnology Reports Third Quarter 2019 Financial Results LOS ANGELES, Calif., Nov. 6, 2019 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2019. Unless otherwise stated, all compa
Read more →PBYIPuma Biotechnology Reports Second Quarter 2019 Financial Results
Puma Biotechnology Reports Second Quarter 2019 Financial Results LOS ANGELES, Calif., Aug. 8, 2019 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2019. Unless otherwise stated, all comparis
Read more →PBYIPuma Biotechnology Reports First Quarter 2019 Financial Results
Puma Biotechnology Reports First Quarter 2019 Financial Results LOS ANGELES, Calif., May 9, 2018 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2019. Unless otherwise stated, all comparison
Read more →PBYIPuma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results
Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results Calif., Feb. 28, 2019 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2018. Unless otherwise state
Read more →PBYIROBBINS ARROYO LLP BRIAN J. ROBBINS (190264) brobbins@robbinsarroyo.com KEVIN A SEELY (199982) kseely@robbinsarroyo.com ASHLEY R. RIFKIN (246602) arifkin@robbinsarroyo.com 600 B Street, Suite 1900 San Diego, CA 92101 Tel
brobbins@robbinsarroyo.com KEVIN A SEELY (199982) kseely@robbinsarroyo.com arifkin@robbinsarroyo.com 600 B Street, Suite 1900 Telephone: (619) 525-3990 Facsimile: (619) 525-3991 Counsel for Plaintiff Arnaud van der Gracht de Rommerswael UNITED STATES DISTRICT COURT CENT
Read more →PBYIPuma Biotechnology Reports Third Quarter 2018 Financial Results
Puma Biotechnology Reports Third Quarter 2018 Financial Results LOS ANGELES, Calif., Nov. 01, 2018 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2018. Unless otherwise stated, all comp
Read more →PBYIPuma Biotechnology Reports Second Quarter 2018 Financial Results
Puma Biotechnology Reports Second Quarter 2018 Financial Results LOS ANGELES, Calif., Aug. 9, 2018 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2018. Unless otherwise stated, all comparis
Read more →PBYIPuma Biotechnology Reports First Quarter 2018 Financial Results
Puma Biotechnology Reports First Quarter 2018 Financial Results LOS ANGELES, Calif., May 9, 2018 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2018. Unless otherwise stated, all compariso
Read more →PBYIPuma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results
Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results Calif., March 1, 2018 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2017. Unless otherwise state
Read more →PBYIPuma Biotechnology Reports Third Quarter 2017 Financial Results Results include the initial sales of NERLYNX in the
Puma Biotechnology Reports Third Quarter 2017 Financial Results Results include the initial sales of Calif., Nov. 9, 2017 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter and nine months ended September 30,
Read more →PBYIPuma Biotechnology Reports Second Quarter 2017 Financial Results
Puma Biotechnology Reports Second Quarter 2017 Financial Results LOS ANGELES, Calif., Aug. 9, 2017 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2017. Unless otherwise stated, all compari
Read more →PBYIPuma Biotechnology Reports First Quarter 2017 Financial Results
Puma Biotechnology Reports First Quarter 2017 Financial Results LOS ANGELES, Calif., May 10, 2017 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2017. Unless otherwise stated, all comparis
Read more →PBYIInterim 5-year DFS in patients initiating neratinib treatment less than 1 year after completing adjuvant trastuzumab 0 6 12 18 24 36 42 48 60 30 54 Disease-free survival (%) Months after randomization 1152 1145 1054 1080
Neratinib / Placebo treatment 0 3 6 9 12 15 18 21 24 Disease-free survival (%) Months after randomization 1152 1145 1047 1100 1023 1063 1002 1035 971 997 936 964 899 929 833 865 No. at risk Neratinib Placebo 100 60 50 80 90 0 70 Two sided P-value = 0.006 HR (95% CI) = 0.63 (0.4
Read more →PBYIPuma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results
Puma Biotechnology Reports Fourth Quarter and Full Year 2016 LOS ANGELES, Calif., March 1, 2017 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2016. Unless otherwise stated, a
Read more →PBYIPuma Biotechnology to Move Stock Exchange Listing to Nasdaq Ticker symbol to remain
Puma Biotechnology to Move Stock Exchange Listing to Nasdaq Ticker symbol to remain PBYI ANGELES, Calif., Dec. 19, 2016 Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it will voluntarily move its stock exchange listing from the New York Stock
Read more →PBYIPuma Biotechnology Reports Third Quarter 2016 Financial Results
Puma Biotechnology Reports Third Quarter 2016 Financial Results LOS ANGELES, Calif., Nov. 9, 2016 Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2016. Unless otherwise stated, all compar
Read more →PBYIPuma Biotechnology Reports Second Quarter 2016 Financial Results
Puma Biotechnology Reports Second Quarter 2016 Financial Results LOS ANGELES, Calif., Aug. 9, 2016 Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2016. Unless otherwise stated, all com
Read more →PBYIInterim 5-Year Analysis of iDFS Data from Phase III ExteNET Trial July 2016 Copyright 2016 Puma Biotechnology Forward-Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning
Interim 5-Year Analysis of iDFS Data from Phase III ExteNET Trial Copyright 2016 Puma Biotechnology Forward-Looking Safe Harbor Statement presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but
Read more →PBYIPuma Biotechnology Reports First Quarter 2016 Financial Results
Puma Biotechnology Reports First Quarter 2016 Financial Results LOS ANGELES, Calif., May 10, 2016 Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2016. Unless otherwise stated, all comparison
Read more →PBYIEvent and Censoring Rules Original Rule Invasive Disease Free Survival (iDFS) events were defined as all recurrent disease events and deaths occurring within 2 years and 28 days post randomization Revised Rule (as per FD
Updated Results from ExteNET Trial Using the Event and Censoring Rule Requested by FDA 1 Copyright 2016 Puma Biotechnology Exhibit 99.1 Event and Censoring Rules Original Rule Invasive Disease Free Survival (iDFS) events were defined as all recurrent disease events and deaths
Read more →PBYIPuma Biotechnology Reports Fourth Quarter and Full Year 2015 Financial Results
Puma Biotechnology Reports Fourth Quarter and Full Year 2015 Financial Results Calif., Feb. 29, 2016 Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2015. Unless otherwise stated
Read more →PBYIAn Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis Copyright 2015 Puma Biotechnology 1
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis Copyright 2015 Puma Biotechnology Diarrhea in ExteNET Trial 1 2 3 4 5 6 7 8 9 10 11 12 Pts w
Read more →PBYIPuma Biotechnology Reports Third Quarter 2015 Financial Results
Puma Biotechnology Reports Third Quarter 2015 Financial Results LOS ANGELES, Calif., Nov. 9, 2015 Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2015. Unless otherwise stated, all compar
Read more →PBYIPuma Biotechnology Reports Second Quarter 2015 Financial Results
Puma Biotechnology Reports Second Quarter 2015 LOS ANGELES, Calif., Aug. 10, 2015 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced financial results for the second quarter ended June 30, 2015. Unless otherwise stated, all comparis
Read more →PBYIPuma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival
Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival LOS ANGELES, Calif., June 1, 2015 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage bio
Read more →PBYIPuma Biotechnology Reports First Quarter 2015 Financial Results
Puma Biotechnology Reports First Quarter 2015 Financial Results LOS ANGELES, Calif., May 11, 2015 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced financial results for the first quarter ended March 31, 2015. Unless otherwise stat
Read more →PBYIPuma Biotechnology Expands Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients
Puma Biotechnology Expands Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients LOS ANGELES, Calif., April 14, 2015 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, has expanded the second cohort from its Phase II cli
Read more →PBYIPuma Biotechnology Initiates Phase II Trial of PB272 in Early Stage HER2-Positive Breast Cancer
Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage HER2-Positive Breast Cancer ANGELES, Calif., Mar. 10, 2015 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the initiation of a Phase II trial of Puma s investigat
Read more →PBYIPuma Biotechnology Reports Fourth Quarter and Full Year 2014 Financial Results
Puma Biotechnology Reports Fourth Quarter and Full Year 2014 Financial Results Calif., Mar. 2, 2015 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2014. Unless
Read more →PBYIPuma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CTRC-AACR San Antonio Breast Cancer Symposium Interim Phase II Results Demonstrate Efficacy of PB272 in Combination with
Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CTRC-AACR San Antonio Breast Cancer Symposium Interim Phase II Results Demonstrate Efficacy of PB272 in Combination with Temsirolimus in HER2+ Metastatic Breast Cancer LOS ANGELES, Calif., D
Read more →PBYIPuma Biotechnology Updates Timeline for Filing New Drug Application NDA Filing Currently Anticipated for Q1 2016
Puma Biotechnology Updates Timeline for Filing New Drug Application NDA Filing Currently Anticipated for Q1 2016 LOS ANGELES, Calif., Dec. 2, 2014 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, today provided an update on the timeline for
Read more →PBYIPuma Biotechnology Announces Positive Top Line Results from PB272 Phase II Trial in HER2 Positive Metastatic Breast Cancer (NEfERTT Trial) Neratinib Achieves Statistically Significant Reduction in Incidence
Puma Biotechnology Announces Positive Top Line Results from PB272 Phase II Trial in HER2 Positive Metastatic Breast Cancer (NEfERTT Trial) Neratinib Achieves Statistically Significant Reduction in Incidence of Central Nervous System LOS ANGELES, Calif., Nov. 13, 2014 Puma Bio
Read more →PBYIPuma Biotechnology Reports Third Quarter 2014 Financial Results
Puma Biotechnology Reports Third Quarter 2014 LOS ANGELES, Calif., Nov. 10, 2014 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced financial results for the third quarter ended September 30, 2014. Unless otherwise stated, all compa
Read more →PBYIPuma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated Non-Small Cell Lung Cancer
Puma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated Non-Small Cell Lung Cancer LOS ANGELES, Calif., Sept. 29, 2014 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that positive initial
Read more →PBYIPuma Biotechnology Reports Second Quarter 2014 Financial Results
Puma Biotechnology Reports Second Quarter 2014 LOS ANGELES, Calif., Aug. 11, 2014 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced financial results for the second quarter ended June 30, 2014. Unless otherwise stated, all comparis
Read more →PBYIPuma Biotechnology Announces Amendment to Neratinib Licensing Agreement with Pfizer
Puma Biotechnology Announces Amendment to Neratinib Licensing Agreement with Pfizer LOS ANGELES, Calif., July 22, 2014 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced an amendment to its licensing agreement with Pfizer for Puma s
Read more →PBYIPuma Biotechnology Announces Presentation of Positive PB272 Phase II Data at the 2014 ASCO Annual Meeting
Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data at the 2014 ASCO Annual Meeting LOS ANGELES, Calif., June 1, 2014 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the presentation of positive results from
Read more →PBYIPuma Biotechnology Expands Cohort in Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients
Puma Biotechnology Expands Cohort in Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients LOS ANGELES, Calif., May 14, 2014 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, has expanded the first cohort from it
Read more →PBYIPuma Biotechnology Reports First Quarter 2014 Financial Results
Puma Biotechnology Reports First Quarter 2014 LOS ANGELES, Calif., May 12, 2014 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced financial results for the first quarter ended March 31, 2014. Unless otherwise stated, all comparison
Read more →PBYIPuma Biotechnology Announces Presentation of Positive PB272 Phase II Data from I-SPY 2 TRIAL Neratinib Graduates from I-SPY 2
Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data from I-SPY 2 TRIAL Neratinib Graduates from I-SPY 2 TRIAL LOS ANGELES, Calif., April 7, 2014 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, today announced the pre
Read more →PBYIPuma Biotechnology Reports Fourth Quarter and Full Year 2013 Financial Results
Puma Biotechnology Reports Fourth Quarter and Full Year 2013 LOS ANGELES, Calif., March 3, 2014 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2013. Unless oth
Read more →PBYIPuma Biotechnology Announces Positive Outcome of European Opposition Proceedings Patent Claims for Treating Cancer with T790M Mutation Upheld
Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings Patent Claims for Treating Cancer with T790M Mutation Upheld LOS ANGELES, Calif., Feb. 6, 2014 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that
Read more →PBYIPuma Biotechnology Reports Positive Top Line Data from I-SPY 2 TRIAL Neratinib Graduates from I-SPY 2
Puma Biotechnology Reports Positive Top Line Data from I-SPY 2 TRIAL Neratinib Graduates from I-SPY 2 TRIAL LOS ANGELES, Calif., Dec. 4, 2013 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, today announced top line results from the Phase I
Read more →PBYIPuma Biotechnology Reports Third Quarter 2013 Financial Results
Puma Biotechnology Reports Third Quarter 2013 LOS ANGELES, Calif., Nov. 12, 2013 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2013. Unless otherwise stated, all
Read more →PBYIPuma Biotechnology Initiates Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients
Puma Biotechnology Initiates Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients LOS ANGELES, Calif., Oct. 4, 2013 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that it initiated a Phase II clinic
Read more →PBYIPuma Biotechnology Reports Second Quarter 2013 Financial Results
Puma Biotechnology Reports Second Quarter 2013 LOS ANGELES, Calif., Aug. 6, 2013 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2013. Unless otherwise stated, all com
Read more →PBYIPuma Biotechnology Initiates Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients Los Angeles, Calif.
Puma Biotechnology Initiates Phase III Trial of PB272 (Neratinib) HER2-Positive Metastatic Breast Cancer Patients Los Angeles, Calif., June 7, 2013 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the initiation of its Phase III c
Read more →PBYIPuma Biotechnology Reports First Quarter 2013 Financial Results
Puma Biotechnology Reports First Quarter 2013 LOS ANGELES, Calif., May 9, 2013 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, reported financial results for the first quarter ended March 31, 2013. Unless otherwise stated, all comparisons
Read more →PBYIPuma Biotechnology Reports Fourth Quarter and Full Year 2012 Financial Results
Puma Biotechnology Reports Fourth Quarter and Full Year 2012 LOS ANGELES, Calif., April 1, 2013 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company ( Puma or the Company ), today announced financial results for the fourth quarter and year ended
Read more →PBYIPuma Biotechnology Announces Agreement with FDA on Special Protocol Assessment for Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients Los Angeles, Calif.
Puma Biotechnology Announces Agreement with FDA on Special Protocol Assessment for Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients Los Angeles, Calif., Feb. 20, 2013 Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceu
Read more →PBYIPuma Biotechnology Announces Upsizing and Pricing of $120 Million Public Offering of Common Stock
Puma Biotechnology Announces Upsizing and Pricing of $120 Million Public Offering of Common Stock LOS ANGELES, Calif., Oct. 18, 2012 Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced the upsizing and pricing of its public offering. The size of th
Read more →Competitive Position
How PBYI ranks across every disease it competes inCompetitive Position is a premium feature
See how PBYI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial